オンコロジー

Isagani (Gani) M. Chico, MD, is Vice President and Global Head for Oncology Therapeutic Expertise, Fortrea Clinical Development Services, based in Baltimore, Maryland. Gani has more than 35 years of experience in oncology clinical drug development from small and medium sized biotechnology companies, CROs and the FDA, focused on planning and execution global oncology clinical development projects from early phase to post approval, leadership of cross-functional strategic teams within medical affairs and clinical development organizations, and management of pharmaceutical, academic and regulatory interactions. Gani earned his medical degree from the University of the Philippines, completed his Internal Medicine residency at the Cook County Hospital in Chicago, and completed his Medical Oncology fellowship training at the National Institutes of Health in Bethesda, MD. 

At Fortrea, Gani leads a dedicated team of more than 50 oncology physicians with an average of 23 years of academic and industry-related clinical experience in countries across Europe, North America, Latin America and Asia. The oncology medical team executes program and study level medical oversight that span early phase clinical development through late-phase and post-marketing studies. Fortrea also offers a group of consultants that provide expertise in specific tumor indications, technologies and drug classes, including study protocol and clinical development planning and strategy, establishment of target product profiles, feasibility and risk assessment.

Laura Vidal, MD, is a certified medical oncologist with extensively experience in oncology drug. She holds two fellowships in Clinical Drug Development from the Royal Marsden hospital, London and the Princess Margaret Hospital, Toronto. She spent 15 years in clinical and academic positions specializing in the field on oncology and drug development. Throughout her career, Dr. Vidal has authored or co-authored dozens of peer-reviewed journal articles and received numerous health and research awards. Her research interests are focused on early phase development of targeted agents, molecular and imaging biomarkers and anticancer immunotherapy. She holds a thesis title from the London University in oncolytic viruses from her pre-clinical and clinical work in reovirus (Reolysin®). 

She joined our company in December 2020. Dr. Laura Vidal is the Medical Head of the Oncology group in EU. She contributes to the development of Fortrea policies involving medical, safety and therapeutics; serves as point of contact for key clients on business and studies oversight; manages relationships with investigators/sites for clinical trials, and mentors clinical research physicians and medical directors across the company.

Geoffrey Kannan, PhD, MD, is an Executive Medical Director in the Oncology Therapeutic Area, Head of the Americas Oncology Team, and Lead for the Pediatric Oncology Medical Science Leadership Center. Dr. Kannan also provides medical and scientific governance to Sponsors, supporting development and execution of oncology clinical trials. Dr. Kannan brings more than 25 years of oncology scientific and medical experience to Fortrea. Dr. Kannan trained as a pediatric hematologist/oncologist and pediatric neuro-oncologist and has served at the University of Miami Miller School of Medicine, the University of Texas M. D. Anderson Cancer Center, Dana-Farber Cancer Institute/Boston Children's Hospital, and on faculty at Harvard Medical School. Dr. Kannan joined Fortrea out of practice as a pediatric neuro-oncologist affiliated with Inova Children's Hospital and Children's National Medical Center. At Fortrea Dr. Kannan leads medical and scientific oncology therapeutic expertise and strategic endeavors for Fortrea's Americas-based oncology physicians, and leads Fortrea's pediatric oncology initiatives, lending an experienced voice to guide industry partners to bring life-saving therapies to children afflicted with cancer.

Kamal Saini, MD, executive medical director at Fortrea Inc., is a board-certified medical oncologist based in Cambridge, United Kingdom, where he also practices part-time at the Addenbrooke's (Cambridge University) Hospital. He contributes to the scientific strategic leadership of the oncology therapeutic area at Fortrea and provides clinical and medical expertise to project teams and other Fortrea departments on clients' drug development projects. He liaises with key opinion leaders and academic cooperative groups with regard to the design, setup, and execution of cancer trials, especially in the breast cancer subdomain. He manages a team of high-performing medical monitors who are a part of the European oncology team. He leads the Precision Medicine and Emerging Therapies Leadership Center at Fortrea, and is also our global Scientific Publications Lead (Oncology). He brings more than 15 years of experience in clinical research and development to Fortrea. He is the author or co-author of several peer-reviewed journal articles. He joined our company in 2015.

Kazuya Iwamoto, MD, PhD, MBA, FACP, is Senior Medical Director for Fortrea in Osaka, Japan. He provides medical and scientific expertise to oncology study teams on clients' drug development projects and contributes to the development of medical strategies and execution of clinical trials. Dr. Iwamoto has more than 25 years of experience as a physician, research clinician and medical director. 

Before joining Fortrea, he was Head of the Medical Division, including Clinical Development and Medical Affairs, for Hospira Japan in Osaka. He previously served as Head of the Medical Division for Biogen Idec, Head of Medical Affairs for Bayer Yakuhin, and Clinical Research Physician for Eli Lilly in Japan. Currently President and Fellow of the Japanese Association of Pharmaceutical Medicine, Dr. Iwamoto joined our company in May 2016.

Krane Huang, MD, is a Senior Medical Director, China Regional Head of Oncology for Fortrea, based in Shanghai, China. Dr. Krane has nearly 20 years of experience as medical oncologist in cancer hospitals, global pharmaceutical industries and CROs, focused on planning and execution of global oncology clinical development projects in all phases (I-III), different drug types and classes. 

Dr. Krane earned his medical degree from Tongji Medical College, Huazhong University of Science & Technology and completed his internal medicine degree and medical oncology fellowship training at Wu Union Hospital. He joined our company in September 2019.